candesartan trityl methyl ester imp

Candesartan trityl methyl ester imp is a synthetic byproduct arising during the esterification step of candesartan synthesis. It features a trityl (triphenylmethyl) group appended to the parent drug's bicyclic scaffold, with a methyl ester substituent at the carboxylic acid terminus. This impurity results from incomplete tritylation or esterification, retaining the tetrazole moiety critical to angiotensin II receptor antagonism. Its trityl substitution introduces steric bulk, altering hydrophobicity relative to the parent compound. This impurity serves as an HPLC reference standard for quantifying process-related impurities in candesartan active pharmaceutical ingredient batches.